Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A T van Oosterom

Showing results (21-30 of 196) with videos related to

Pageof 20
Sort By:
Pharmaceutisch Weekblad. Scientific Edition|August 23, 1985
Predictive testing in cancer chemotherapy. II. In vitroP H Slee, A T Van Oosterom, E A De Bruijn
Thrombosis and Haemostasis|June 30, 1976
The influence of the thyroid function on the metabolic rate of prothrombin, factor VII, and factor X in the ratA T van Oosterom, H Mattie, W T Hermens, et al.
Anti-Cancer Drugs|June 1, 1995
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experienceA T van Oosterom, D Schrijvers, D ] Schriivers D [corrected to Schrijvers
Current Opinion in Oncology|July 1, 1997
Soft tissue sarcoma in adultsL Y Dirix, P Vermeulen, I De Wever, et al.
Cancer Treatment Reviews|December 1, 1983
Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II studyH T Mouridsen, C Rose, M A Nooy, et al.
Cancer Research|June 1, 1987
cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)A M Fichtinger-Schepman, A T van Oosterom, P H Lohman, et al.
Medical and Pediatric Oncology|January 1, 1983
Unusual metastatic pattern in testicular malignant teratomaH A Wassenaar, R A Roos, P J Spaander, et al.
Mutation Research|January 1, 1987
Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay?A M Fichtinger-Schepman, A T van Oosterom, P H Lohman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG)M Van Glabbeke, A T van Oosterom, W Steward, et al.
Clinical Radiology|November 1, 1984
Scintigraphic peritoneography in advanced ovarian malignancies: its value for chemotherapeutic distribution studiesB J Van Weelde, E K Pauwels, B Jones, et al.
Pageof 20

Showing results (21-30 of 196) with videos related to

Sort By:
Pageof 20
Pharmaceutisch Weekblad. Scientific Edition|August 23, 1985
Predictive testing in cancer chemotherapy. II. In vitroP H Slee, A T Van Oosterom, E A De Bruijn
Thrombosis and Haemostasis|June 30, 1976
The influence of the thyroid function on the metabolic rate of prothrombin, factor VII, and factor X in the ratA T van Oosterom, H Mattie, W T Hermens, et al.
Anti-Cancer Drugs|June 1, 1995
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experienceA T van Oosterom, D Schrijvers, D ] Schriivers D [corrected to Schrijvers
Current Opinion in Oncology|July 1, 1997
Soft tissue sarcoma in adultsL Y Dirix, P Vermeulen, I De Wever, et al.
Cancer Treatment Reviews|December 1, 1983
Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II studyH T Mouridsen, C Rose, M A Nooy, et al.
Cancer Research|June 1, 1987
cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)A M Fichtinger-Schepman, A T van Oosterom, P H Lohman, et al.
Medical and Pediatric Oncology|January 1, 1983
Unusual metastatic pattern in testicular malignant teratomaH A Wassenaar, R A Roos, P J Spaander, et al.
Mutation Research|January 1, 1987
Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay?A M Fichtinger-Schepman, A T van Oosterom, P H Lohman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG)M Van Glabbeke, A T van Oosterom, W Steward, et al.
Clinical Radiology|November 1, 1984
Scintigraphic peritoneography in advanced ovarian malignancies: its value for chemotherapeutic distribution studiesB J Van Weelde, E K Pauwels, B Jones, et al.
Pageof 20